TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04565184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine combination
Description: Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether, Lumefantrine Drug Combination
Description: Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
Study: NCT03708627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: Bimatoprost, aka Lumigan, one drop in one eye nightly
Study: NCT01410539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT guided PCI
Description: OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided medical therapy
Description: OCT guided medical therapy. Tailored antiplatelet therapy.
Study: NCT02913040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: Oxygen delivery through Heated Humidified High Flow Nasal Cannula
Study: NCT02500966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LEEP
Description: Loop Electrosurgical Excision Procedure
Study: NCT04125758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Brief audio recordings discussing mindfulness or guided mindfulness practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tracking time spent on mobile device
Description: Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
Study: NCT02534623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Study: NCT01729429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV brochure, recall, reminders
Description: * HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Adolescent Vaccine Brochure
Description: Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
Study: NCT01832038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day.
Study: NCT03211858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
Study: NCT02913040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Nasal Prongs
Description: Oxygen delivery through Low Flow Nasal Prongs
Study: NCT02160353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, Prednisolone
Study: NCT02803762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
Study: NCT00772083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational brochure
Description: This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pamphlet
Description: The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
Study: NCT00415454

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP
Description: Single injection on day 1 at one of five dose levels
Study: NCT01406925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream
Description: Cream for single-dose intra-anal application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream
Description: Cream for single-dose intra-anal application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream
Description: Cream for single-dose intra-anal application
Study: NCT00174291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
Study: NCT04158791

Intervention type: PROCEDURE
Intervention: pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling
Description: 25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
Study: NCT01160640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg PO bid x 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg PO bid x 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: metronidazole 500 mg PO bid x 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: placebo oral capsule PO bid x 14 days
Study: NCT01833169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
Study: NCT02357927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-AFTERc
Description: 20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
Study: NCT01526122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G0041(75/100mg)
Description: G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
Study: NCT02357927

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: telephone call
Description: this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
Study: NCT04870164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensovibep
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensovibep
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensovibep
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensovibep
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One administration at day 1 by infusion.
Study: NCT01526122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel & Aspirin
Description: Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules, PO
Study: NCT00519779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 supplementation
Description: 2.5 g/day omega-3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral omega-3 fish oil placebo
Description: to match experimental dosage
Study: NCT04949685

Intervention type: PROCEDURE
Intervention: plantar plate repair
Description: surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
Study: NCT03845764

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid on-site evaluation
Description: Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
Study: NCT05108051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: ZSP1273 tablets 600mg administered orally once daily
Study: NCT03751228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Swish and expectorate after tasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Pharmaceutical Ingredient
Description: Swish and expectorate after tasting
Study: NCT05108051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: ZSP1273 tablets 600mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: ZSP1273 tablets 600mg administered orally once daily
Study: NCT03248843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
Study: NCT03304418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~* Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~* Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~* Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~* Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)
Study: NCT03970213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Description: IV TXA given during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: IV saline given during surgery
Study: NCT05108051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75mg administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75mg administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75mg administered orally twice daily
Study: NCT04302675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention, Maternal Immunization
Description: This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study.
Study: NCT05355922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical electrostimulation of the quadriceps muscle
Description: Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electrical electrostimulation of the quadriceps muscle (placebo)
Description: Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
Study: NCT02623556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm
Description: All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm
Description: All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm
Description: All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm
Description: All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
Study: NCT01248481

Intervention type: DRUG
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
Study: NCT02892032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Training
Description: Subjects are taught to disengage attention from a certain stimuli

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Attention Modification Training
Description: Subjects are exposed to two stimuli, but attention is not manipulated in any way
Study: NCT04453228

Intervention type: OTHER
Intervention: Classification statistics
Description: We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc

Intervention type: OTHER
Intervention: Classification statistics
Description: We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
Study: NCT00892229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (given buccally)
Description: 400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
Study: NCT03526731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guided quadratus lumborum block
Description: ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
Study: NCT00892229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (given vaginally)
Description: 400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (given vaginally)
Description: 400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
Study: NCT00057876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Induction: Patients receive the first cycle of gemcitabine 1000 mg/m\^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m\^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Induction: Patients receive gemcitabine 600 mg/m\^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy.
Study: NCT04092569

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-medical consultation structured diabetes self-care education programme
Description: The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki.
Study: NCT04173234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
Study: NCT00969904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600 mg TID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet TID for 12 weeks
Study: NCT01813955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine or placebo
Description: Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
Study: NCT04602962

Intervention type: PROCEDURE
Intervention: fertility preservation, several methods
Description: fertility preservation using assisted reproductive techniques or not
Study: NCT02725203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activate
Description: The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
Study: NCT02889042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and biological assessment
Description: performing a MRI and a biological assessment

Intervention type: OTHER
Group type: OTHER
Intervention: MRI and biological assessment
Description: performing a MRI and a biological assessment

Intervention type: OTHER
Group type: OTHER
Intervention: MRI and biological assessment
Description: performing a MRI and a biological assessment

Intervention type: OTHER
Group type: OTHER
Intervention: MRI and biological assessment
Description: performing a MRI and a biological assessment